Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18734 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Sarah A Milgrom und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Colorado, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Hodgkin Disease. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
The Children's Oncology Group AHOD0831 study used a positron emission tomography (PET) response‐adapted approach in high‐risk Hodgkin lymphoma, whereby slow early responders (SERs) received more intensive therapy than rapid early responders (RERs). We explored if baseline PET‐based characteristics would improve risk stratification. Of 166 patients enrolled in the COG AHOD0831 study, 94 (57%) had baseline PET scans evaluable for quantitative analysis. For these patients, total body metabolic tumour volume (MTV), total lesion glycolysis (TLG), maximum standardized uptake value (SUV max ) and peak SUV (SUV peak ) were obtained. MTV/TLG thresholds were an SUV of 2.5 (MTV 2.5 /TLG 2.5 ) and 40% of the tumour SUV max (MTV 40% /TLG 40% ). TLG 2.5 was associated with event‐free survival (EFS) in the complete cohort ( p = 0.04) and in RERs ( p = 0.01), but not in SERs ( p = 0.8). The Youden index cut‐off for TLG 2.5 was 1841. Four‐year EFS was 92% for RER/TLG 2.5 up to 1841, 60% for RER/TLG 2.5 greater than 1841, 74% for SER/TLG 2.5 up to 1841 and 79% for SER/TLG 2.5 greater than 1841. Second EFS for RER/TLG 2.5 up to 1841 was 100%. Thus, RERs with a low baseline TLG 2.5 experienced excellent EFS with less intensive therapy, whereas RERs with a high baseline TLG 2.5 experienced poor EFS. These findings suggest that patients with a high upfront tumour burden may benefit from intensified therapy, even if they achieve a RER.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, University of Colorado, Aurora, Colorado, USA.
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
- Division of Nuclear Medicine, Department of Radiology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Children's Oncology Group, Statistics and Data Center, Department of Biostatistics, University of Florida, Gainesville, Florida, USA.
- Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea.
- Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, Florida, USA.
ORCID-Profile: Sarah A Milgrom, Bradford S Hoppe, David Hodgson, Andrea C Lo, Kara M Kelly
Förderung
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Milgrom, S. A., Kim, J., Pei, Q., Lee, I., Hoppe, B. S., Wu, Y., Hodgson, D., Kessel, S., McCarten, K. M., Roberts, K., Lo, A. C., Cole, P. D., Kelly, K. M., & Cho, S. Y. (2023). Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study. British Journal of Haematology. https://doi.org/10.1111/bjh.18734
Vancouver
Milgrom SA, Kim J, Pei Q, Lee I, Hoppe BS, Wu Y, et al. Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study. British Journal of Haematology. 2023. doi:10.1111/bjh.18734
BibTeX
@article{Milgrom2023,
author = {Milgrom, Sarah A and Kim, Jihyun and Pei, Qinglin and Lee, Inki and Hoppe, Bradford S and Wu, Yue and Hodgson, David and Kessel, Sandy and McCarten, Kathleen M and Roberts, Kenneth and Lo, Andrea C and Cole, Peter D and Kelly, Kara M and Cho, Steve Y},
title = {Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18734}
}
EUVIMED